Soluble HLA-G dampens CD94/NKG2A expression and function and differentially modulates chemotaxis and cytokine and chemokine secretion in CD56 brightand CD56dim NK cells

Blood

Volumn 118, Issue 22, 2011, Pages 5840-5850

  Morandi, Fabio ^a   Ferretti, Elisa ^a   Castriconi, Roberta ^b   Dondero, Alessandra ^b   Petretto, Andrea ^c   Bottino, Cristina ^a,b   Pistoia, Vito ^a  

^a G GASLINI INSTITUTE   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c Mass Spectrometry Core Facility   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD56 ANTIGEN; CD94 ANTIGEN; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CX3CR1; CHEMOKINE RECEPTOR CXCR3; CHEMOKINE RECEPTOR CXCR5; CXCL1 CHEMOKINE; CXCL11 CHEMOKINE; CXCL3 CHEMOKINE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; HLA G ANTIGEN; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 2; NATURAL KILLER CELL RECEPTOR NKG2A; STAT5 PROTEIN;

ARTICLE; BLOOD; CELL DIFFERENTIATION; CELL FUNCTION; CELL SURFACE; CHEMOTAXIS; CONTROLLED STUDY; CYTOKINE RELEASE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; NATURAL KILLER CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TONSIL CELL; UPREGULATION;

EID: 82155184509     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-05-352393     Document Type: Article

References (50)

1. Walzer T, Dalod M, Robbins SH, Zitvogel L, Vivier E. Natural-killer cells and dendritic cells: "l'union fait la force." Blood. 2005;106(7):2252-2258. (Pubitemid 41510793)
2. Moretta A, Marcenaro E, Sivori S, Della Chiesa M, Vitale M, Moretta L. Early liaisons between cells of the innate immune system in inflamed peripheral tissues. Trends Immunol. 2005;26(12):668-675. (Pubitemid 41628200)
3. Trinchieri G. Biology of natural killer cells. Adv Immunol. 1989;47:187-376. (Pubitemid 20010960)
4. Vivier E, Raulet DH, Moretta A, et al. Innate or adaptive immunity? The example of natural killer cells. Science. 2011;331(6013):44-49.
5. Inngjerdingen M, Damaj B, Maghazachi AA. Expression and regulation of chemokine receptors in human natural killer cells. Blood. 2001;97(2): 367-375. (Pubitemid 32060319)
6. Parolini S, Santoro A, Marcenaro E, et al. The role of chemerin in the colocalization of NK and dendritic cell subsets into inflamed tissues. Blood. 2007;109(9):3625-3632. (Pubitemid 46641708)
7. Yoneda O, Imai T, Goda S, et al. Fractalkine-mediated endothelial cell injury by NK cells. J Immunol. 2000;164(8):4055-4062. (Pubitemid 30215060)
8. Cooper MA, Fehniger TA, Turner SC, et al. Human natural killer cells: a unique innate immunoregulatory role for the CD56(bright) subset. Blood. 2001;97(10):3146-3151.
9. Fehniger TA, Cooper MA, Nuovo GJ, et al. CD56bright natural killer cells are present in human lymph nodes and are activated by T cell-derived IL-2: a potential new link between adaptive and innate immunity. Blood. 2003;101(8):3052-3057. (Pubitemid 36857995)
10. Yu J, Wei M, Mao H, et al. CD94 defines phenotypically and functionally distinct mouse NK cell subsets. J Immunol. 2009;183(8):4968-4974.
11. O'Callaghan CA, Bell JI. Structure and function of the human MHC class Ib molecules HLA-E, HLA-F and HLA-G. Immunol Rev. 1998;163:129-138. (Pubitemid 28327866)
12. Fujii T, Ishitani A, Geraghty DE. A soluble form of the HLA-G antigen is encoded by a messenger ribonucleic acid containing intron 4. J Immunol. 1994;153(12):5516-5524. (Pubitemid 24377687)
13. Pistoia V, Morandi F, Wang X, Ferrone S. Soluble HLA-G: are they clinically relevant? Semin Cancer Biol. 2007;17(6):469-479. (Pubitemid 350064562)
14. Faure M, Long EO. KIR2DL4 (CD158d), an NK cell-activating receptor with inhibitory potential. J Immunol. 2002;168(12):6208-6214. (Pubitemid 34620040)
15. Rouas-Freiss N, Goncalves RM, Menier C, Dausset J, Carosella ED. Direct evidence to support the role of HLA-G in protecting the fetus from maternal uterine natural killer cytolysis. Proc Natl Acad Sci U S A. 1997;94(21):11520- 11525. (Pubitemid 27451031)
16. Rouas-Freiss N, Moreau P, Menier C, LeMaoult J, Carosella ED. Expression of tolerogenic HLA-G molecules in cancer prevents antitumor responses. Semin Cancer Biol. 2007;17(6):413-421. (Pubitemid 350064561)
17. Lafon M, Prehaud C, Megret F, et al. Modulation of HLA-G expression in human neural cells after neurotropic viral infections. J Virol. 2005;79(24): 15226-15237. (Pubitemid 43032305)
18. Poehlmann TG, Schaumann A, Busch S, et al. Inhibition of term decidual NK cell cytotoxicity by soluble HLA-G1. Am J Reprod Immunol. 2006; 56(5-6):275-285. (Pubitemid 44669323)
19. Lindaman A, Dowden A, Zavazava N. Soluble HLA-G molecules induce apoptosis in natural killer cells. Am J Reprod Immunol. 2006;56(1): 68-76. (Pubitemid 43871640)
20. Lesport E, Baudhuin J, LeMaoult J, et al. Human melanoma cell secreting human leukocyte antigen- G5 inhibit natural killer cell cytotoxicity by impairing lytic granules polarization toward target cell. Hum Immunol. 2009;70(12):1000-1005.
21. Yu Y, Wang Y, Feng M. Human leukocyte antigen- G1 inhibits natural killer cytotoxicity through blocking the activating signal transduction pathway and formation of activating immunologic synapse. Hum Immunol. 2008;69(1):16-23.
22. Li C, Houser BL, Nicotra ML, Strominger JL. HLA-G homodimer-induced cytokine secretion through HLA-G receptors on human decidual macrophages and natural killer cells. Proc Natl Acad Sci U S A. 2009;106(14):5767-5772.
23. Morel E, Bellon T. HLA class I molecules regulate IFN-gamma production induced in NK cells by target cells, viral products, or immature dendritic cells through the inhibitory receptor ILT2/CD85j. J Immunol. 2008;181(4):2368-2381.
24. van der Meer A, Lukassen HG, van Cranenbroek B, et al. Soluble HLA-G promotes Th1-type cytokine production by cytokine-activated uterine and peripheral natural killer cells. Mol Hum Reprod. 2007;13(2): 123-133. (Pubitemid 46152599)
25. Rajagopalan S, Bryceson YT, Kuppusamy SP, et al. Activation of NK cells by an endocytosed receptor for soluble HLA-G. PLoS Biol. 2006;4(1): e9.
26. Kanai T, Fujii T, Kozuma S, et al. Soluble HLA-G influences the release of cytokines from allogeneic peripheral blood mononuclear cells in culture. Mol Hum Reprod. 2001;7(2):195-200. (Pubitemid 32148347)
27. Naji A, Le Rond S, Durrbach A, et al. CD3+CD4low and CD3+CD8low are induced by HLA-G: novel human peripheral blood suppressor T-cell subsets involved in transplant acceptance. Blood. 2007;110(12):3936-3948. (Pubitemid 350248449)
28. Morandi F, Ferretti E, Bocca P, Prigione I, Raffaghello L, Pistoia V. A novel mechanism of soluble HLA-G mediated immune modulation: downregulation of T cell chemokine receptor expression and impairment of chemotaxis. PLoS One. 2010;5(7):e11763.
29. Frank DA, Robertson MJ, Bonni A, Ritz J,Greenberg ME. Interleukin 2 signaling involves the phosphorylation of Stat proteins. Proc Natl Acad Sci U S A. 1995;92(17):7779-7783.
30. Flier J, Boorsma DM, van Beek PJ, et al. Differential expression of CXCR3 targeting chemokines CXCL10, CXCL9, and CXCL11 in different types of skin inflammation. J Pathol. 2001;194(4):398-405. (Pubitemid 32782663)
31. Wuest TR, Carr DJ. Dysregulation of CXCR3 signaling due to CXCL10 deficiency impairs the antiviral response to herpes simplex virus 1 infection. J Immunol. 2008;181(11):7985-7993.
32. Sentman CL, Meadows SK, Wira CR, Eriksson M. Recruitment of uterine NK cells: induction of CXC chemokine ligands 10 and 11 in human endometrium by estradiol and progesterone. J Immunol. 2004;173(11):6760-6766. (Pubitemid 39541062)
33. Ottaviani C, Nasorri F, Bedini C, de Pita O, Girolomoni G, Cavani A. CD56brightCD16(-) NK cells accumulate in psoriatic skin in response to CXCL10 and CCL5 and exacerbate skin inflammation. Eur J Immunol. 2006;36(1):118-128. (Pubitemid 43116398)
34. Carbone T, Nasorri F, Pennino D, et al. CD56highCD16-CD62L-NK cells accumulate in allergic contact dermatitis and contribute to the expression of allergic responses. J Immunol. 2010;184(2):1102-1110.
35. Fainardi E, Rizzo R, Melchiorri L, et al. Intrathecal synthesis of soluble HLA-G and HLA-I molecules are reciprocally associated to clinical and MRI activity in patients with multiple sclerosis. Mult Scler. 2006;12(1):2-12. (Pubitemid 43169232)
36. Prigione I, Penco F, Martini A, Gattorno M, Pistoia V, Morandi F. HLA-G and HLA-E in patients with juvenile idiopathic arthritis. Rheumatology. 2011;50(5):966-972.
37. Pokkali S, Das SD, Selvaraj A. Differential upregulation of chemokine receptors on CD56 NK cells and their transmigration to the site of infection in tuberculous pleurisy. FEMS Immunol Med Microbiol. 2009;55(3):352-360.
38. Megjugorac NJ, Young HA, Amrute SB, Olshalsky SL, Fitzgerald-Bocarsly P. Virally stimulated plasmacytoid dendritic cells produce chemokines and induce migration of T and NK cells. J Leukoc Biol. 2004;75(3):504-514. (Pubitemid 38316382)
39. Weiss JM, Back TC, Scarzello AJ, et al. Successful immunotherapy with IL-2/anti-CD40 induces the chemokine-mediated mitigation of an immunosuppressive tumor microenvironment. Proc Natl Acad Sci U S A. 2009;106(46):19455-19460.
40. Fraticelli P, Sironi M, Bianchi G, et al. Fractalkine (CX3CL1) as an amplification circuit of polarized Th1 responses. J Clin Invest. 2001;107(9):1173-1181. (Pubitemid 32422914)
41. Infante-Duarte C, Weber A, Kratzschmar J, et al. Frequency of blood CX3CR1-positive natural killer cells correlates with disease activity in multiple sclerosis patients. FASEB J. 2005;19(13): 1902-1904. (Pubitemid 41598789)
42. Umehara H, Tanaka M, Sawaki T, et al. Fractalkine in rheumatoid arthritis and allied conditions. Mod Rheumatol. 2006;16(3):124-130. (Pubitemid 43871686)
43. Yu YR, Fong AM, Combadiere C, Gao JL, Murphy PM, Patel DD. Defective antitumor responses in CX3CR1-deficient mice. Int J Cancer. 2007;121(2):316-322. (Pubitemid 46917700)
44. LeMaoult J, Zafaranloo K, Le Danff C, Carosella ED. HLA-G up-regulates ILT2, ILT3, ILT4, and KIR2DL4 in antigen presenting cells, NK cells, and T cells. FASEB J. 2005;19(6):662-664. (Pubitemid 40471278)
45. Borrego F, Masilamani M, Kabat J, Sanni TB, Coligan JE. The cell biology of the human natural killer cell CD94/NKG2A inhibitory receptor. Mol Immunol. 2005;42(4):485-488. (Pubitemid 39655958)
46. Lee N, Goodlett DR, Ishitani A, Marquardt H, Geraghty DE. HLA-E surface expression depends on binding of TAP-dependent peptides derived from certain HLA class I signal sequences. J Immunol. 1998;160(10):4951-4960. (Pubitemid 28215330)
47. Hofmeister V, Weiss EH. HLA-G modulates immune responses by diverse receptor interactions. Semin Cancer Biol. 2003;13(5):317-323. (Pubitemid 38160930)
48. Llano M, Lee N, Navarro F, et al. HLA-E-bound peptides influence recognition by inhibitory and triggering CD94/NKG2 receptors: preferential response to an HLA-G-derived nonamer. Eur J Immunol. 1998;28(9):2854-2863. (Pubitemid 28425243)
49. Mailloux AW, Young MR. NK-dependent increases in CCL22 secretion selectively recruits regulatory T cells to the tumor microenvironment. J Immunol. 2009;182(5):2753-2765.
50. Menier C, Guillard C, Cassinat B, Carosella ED, Rouas-Freiss N. HLA-G turns off erythropoietin receptor signaling through JAK2 and JAK2 V617F dephosphorylation: clinical relevance in polycythemia vera. Leukemia. 2008;22(3):578-584. (Pubitemid 351386728)